Conference Coverage

SSRI tied to improved cognition in comorbid depression, dementia


 

FROM CTAD 2022

Small trial, open-label design

In a comment, Claire Sexton, DPhil, senior director of scientific programs and outreach at the Alzheimer’s Association, said the study “reflects a valuable aspect of treatment research because of the close connection between depression and dementia. Depression is a known risk factor for dementia, including Alzheimer’s disease, and those who have dementia may experience depression.”

senior director of scientific programs and outreach at the Alzheimer’s Association Alzheimer’s Association

Dr. Claire Sexton

She cautioned, however, that the trial was small and had an open-label design instead of the “gold standard” of a double-blinded trial with a control group.

The study was funded by Lundbeck, where Dr. Christensen is an employee. Another author is a Lundbeck employee, and a third author reported various disclosures. Dr. Sexton reported no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

ED visits for kids with suicidal thoughts increasing: Study
MDedge Psychiatry
The importance of connection and community
MDedge Psychiatry
Long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants: A look forward
MDedge Psychiatry
Local-level youth suicides reflect mental health care shortages
MDedge Psychiatry
Should residents be taught how to prescribe monoamine oxidase inhibitors?
MDedge Psychiatry
Psychedelics for treating psychiatric disorders: Are they safe?
MDedge Psychiatry
Optimal psychiatric treatment: Target the brain and avoid the body
MDedge Psychiatry
Strong two-way link between epilepsy and depression
MDedge Psychiatry
Clinical factors drive hospitalization after self-harm
MDedge Psychiatry
Mood stabilizers, particularly lithium, potential lifesavers in bipolar disorder
MDedge Psychiatry